| Kinaction (masitinib) / AB Science |
2015-000897-36: A study to compare masitinib in combination with irinotecan to placebo in combination with irinotecan in the treatment of patients with esophagogastric adenocarcinoma Κλινική μελέτη για τη σύγκριση της μασιτινίμπης σε συνδυασμό με ιρινοτεκάνη έναντι του συνδυασμού placebo με ιρινοτεκάνη στη θεραπεία ασθενών με οισοφαγογαστρικό αδενοκαρκίνωμα |
|
|
| Ongoing | 3 | 364 | Europe | Masitinib, Irinotecan, AB1010, INEOF00997, Film-coated tablet, Concentrate for solution for infusion, IRINOTECAN/DEMO | AB science, AB science | Πatients with advanced-stage esophagogastric adenocarcinoma who have relapsed after first-line chemotherapy Ασθενείς με προχωρημένου σταδίου οισοφαγογαστρικό αδενοκαρκίνωμα οι οποίοι υποτροπίασαν μετά από την πρώτης γραμμής χημειοθεραπεία, Εsophagogastric adenocarcinoma Οισοφαγογαστρικό αδενοκαρκίνωμα, Diseases [C] - Digestive System Diseases [C06] | | | | |
2021-002179-21: A phase 3 study to evaluate the safety and efficacy of masitinib as add-on therapy in patients with mild to moderate Alzheimer's disease treated with standard of care: cholinesterase inhibitors, memantine |
|
|
| Not yet recruiting | 3 | 600 | Europe | Masitinib, AB1010, Film-coated tablet | AB Science, ABScience, AB Science, ABScience | Alzheimer's disease, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Recruiting | 3 | 495 | Europe, US, RoW | Masitinib (6.0), AB1010, Riluzole, Rilutek, Placebo, Placebo Oral Tablet, Masitinib (4.5) | AB Science | Amyotrophic Lateral Sclerosis | 12/23 | 12/23 | | |
| Recruiting | 3 | 140 | Europe, RoW | Masitinib, AB1010, Placebo, Best Supportive Care | AB Science | Indolent Systemic Mastocytosis | 12/24 | 06/25 | | |
| Recruiting | 3 | 800 | Europe, RoW | Placebo, Placebo Oral Tablet, Masitinib (4.5), AB1010 | AB Science | Progressive Multiple Sclerosis | 12/25 | 12/25 | | |
NCT05564169: Masitinib in Patients With Mild to Moderate Alzheimer's Disease |
|
|
| Not yet recruiting | 3 | 600 | Europe | Placebo, Placebo Oral Tablet, Masitinib (4.5), AB1010, Standard of care | AB Science | Alzheimer Disease | 12/26 | 12/26 | | |
2010-021091-28: A clinical study to determine whether a new drug masitinib is safe and effective in cancer of the white blood cells. |
|
|
| Ongoing | 2/3 | 267 | Europe, RoW | Masitinib mesylate, Gemcitabine, Dexamethasone, AB1010, Film-coated tablet, Powder for infusion, Tablet, Gemcitabine, Dexamethasone | AB Science, AB Science | Relapsed or refractory peripheral T-cell lymphoma, Cancer of the white blood cells (T-lymphocytes), Diseases [C] - Cancer [C04] | | | | |
2012-004222-25: Comparison of efficacy of masitinib versus placebo in the treatment of Crohn's disease |
|
|
| Ongoing | 2/3 | 450 | Europe | Masitinib, AB1010, Film-coated tablet | AB Science, AB Science | Crohn's disease, Inflammatory bowel disease, Diseases [C] - Digestive System Diseases [C06] | | | | |
2010-022793-14: A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate the efficacy and safety of masitinib in combination with 5-fluorouracil (5-FU) or capecitabine, or masitinib in combination with irinotecan, or masitinib in combination with irinotecan, 5-fluorouracil (5-FU) and folinic acid (FOLFIRI protocol), as second line chemotherapy in patients with gastric or gastro-oesophageal junction metastatic adenocarcinoma. |
|
|
| Not yet recruiting | 2 | 57 | Europe | masitinib, Irinotecan, AB1010, Film-coated tablet, Solution for infusion, Irinotecan/Campto®/Camptosar® | AB Science | gastric or gastro-oesophageal junction metastatic adenocarcinoma | | | | |
2010-020603-79: Evaluation of masitinib in acute ischemic stroke Evaluación de masitinib en pacientes con ictus isquémico agudo |
|
|
| Ongoing | 2 | 45 | Europe | masitinib, AB1010 tablets, | AB Science, ABScience | patients suffering from Acute Ischemic Stroke Pacientes con ictus isquémico agudo | | | | |
2012-005586-13: A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD) Estudio de fase IIa prospectivo, multicéntrico, randomizado, doble ciego, y controlado con placebo para comparar la eficacia y seguridad del tratamiento con masitinib durante de 24 semanas frente a placebo en pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) |
|
|
| Ongoing | 2 | 30 | Europe | MASITINIB, AB1010, | AB SCIENCE, AB Science, AB SCIENCE, AB Science | Patients with severe COPD Pacientes con EPOC grave | | | | |
2021-005406-96: A 24-week study to compare efficacy and safety of oral masitinib to placebo in the treatment of patients with severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatment |
|
|
| Ongoing | 2 | 78 | Europe | AB1010 Tablets, AB1010 Tablets, Film-coated tablet | AB Science, AB Science | severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatment, severe mast cell activation syndrome (MCAS), Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT04622865 / 2020-001635-27: Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19 |
|
|
| Recruiting | 2 | 200 | Europe | Masitinib, AB1010, Isoquercetin, quercetin-3-O-glucoside, isotrifoliin, Best Supportive Care, BSC | AB Science | SARS-CoV 2, COVID-19, Coronavirus Disease 2019 | 12/23 | 12/23 | | |
NCT05047783: Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 |
|
|
| Recruiting | 2 | 78 | Europe, RoW | Masitinib Mesylate, Masitinib, AB1010, Placebo | AB Science | Covid19, SARS-CoV2 Infection, Coronavirus Disease 2019 | 12/23 | 12/23 | | |
NCT05449444: Masitinib for the Treatment of Severe Mast Cell Activation Syndrome |
|
|
| Recruiting | 2 | 72 | Europe, US | Masitinib 4.5 mg/kg/day, AB1010, Placebo, Placebo Oral Tablet, Best supportive care, BSC, Masitinib 6.0 mg/kg/day | AB Science | Mast Cell Activation Syndrome | 12/24 | 12/24 | | |
2010-022620-77: Evaluation of safety and efficacy of masitinib combined with etoposide or irinotecan in patients with relapsing liver cancer Evaluación de la seguridad y eficacia de masitinib combinada con etopósido o irinotecán en pacientes con cáncer de hígado recurrente |
|
|
| Ongoing | 1/2 | 36 | Europe | masitinib, etoposide, irinotecan, AB1010, Film-coated tablet, Solution for infusion, Solution for injection, Toposar®, VePesid®, Etopophos®, Camptosar | AB Science, , AB Science | hepatocellular carcinoma, Hepatic cancer Cáncer de Hígado, Diseases [C] - Cancer [C04] | | | | |
| EDP-235 / Enanta Pharma |
| Completed | 2 | 231 | Europe, US | EDP-235, Placebo | Enanta Pharmaceuticals, Inc | COVID-19 | 02/23 | 06/23 | | |
NCT05594615: Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects |
|
|
| Completed | 1 | 24 | US | EDP-235, Midazolam, Rosuvastatin, Caffeine | Enanta Pharmaceuticals, Inc | COVID-19 | 11/22 | 11/22 | | |
NCT05594602: Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects. |
|
|
| Completed | 1 | 36 | US | EDP-235, Itraconazole, Carbamazepine, Quinidine | Enanta Pharmaceuticals, Inc | COVID-19 | 12/22 | 12/22 | | |
| lufotrelvir (PF-07304814) / Pfizer |
| Completed | 3 | 2753 | Europe, US, RoW | LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, AZD8895 + AZD1061, MP0420, ensovibep, PF-07304814 | National Institute of Allergy and Infectious Diseases (NIAID), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), University of Copenhagen, Medical Research Council, Kirby Institute, Washington D.C. Veterans Affairs Medical Center, AIDS Clinical Trials Group, National Heart, Lung, and Blood Institute (NHLBI), US Department of Veterans Affairs, Prevention and Early Treatment of Acute Lung Injury, Cardiothoracic Surgical Trials Network, Eli Lilly and Company, Vir Biotechnology, Inc., GlaxoSmithKline, Brii Biosciences Limited, AstraZeneca, Molecular Partners AG, Pfizer, University of Minnesota | Covid19 | 04/22 | 07/23 | | |
NCT05780541: PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) |
|
|
| Terminated | 3 | 58 | Europe, US | PF-07304814, Placebo, Remdesivir, Veklury | National Institute of Allergy and Infectious Diseases (NIAID), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), University of Copenhagen, Medical Research Council, Kirby Institute, Washington D.C. Veterans Affairs Medical Center, AIDS Clinical Trials Group, National Heart, Lung, and Blood Institute (NHLBI), US Department of Veterans Affairs, Prevention and Early Treatment of Acute Lung Injury, Cardiothoracic Surgical Trials Network, Pfizer, University of Minnesota | COVID-19 | 04/22 | 07/23 | | |
| bofutrelvir (FB2001) / Frontier Biotech |
NCT05675072: Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19 |
|
|
| Recruiting | 2/3 | 1336 | RoW | FB2001, FB2001 for Inhalation, FB2001 placebo, placebo | Frontier Biotechnologies Inc. | Mild to Moderate COVID-19 | 09/23 | 12/23 | | |
NCT05445934: Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study) |
|
|
| Recruiting | 2/3 | 1188 | RoW | FB2001, DC402234, FB2001 placebo | Frontier Biotechnologies Inc. | COVID-19 | 11/23 | 12/23 | | |
NCT05415241: Exploratory Study of Aerosol Inhalation of FB2001 for Post-exposure Prophylaxis of COVID-19 Close Contacts |
|
|
| Not yet recruiting | 1/2 | 60 | NA | FB2001 | Ruijin Hospital, Frontier Biotechnologies Inc., Shanghai Center for Disease Control and Prevention | Close Contact Transmission | 08/22 | 12/22 | | |
| Pentarlandir (SNB011) / SyneuRx |
NCT04911777: Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19 |
|
|
| Recruiting | 2 | 90 | US | Pentarlandir™ UPPTA, Placebo | SyneuRx International (Taiwan) Corp | Coronavirus Disease 2019 | 12/21 | 03/22 | | |
| Paxlovid (nirmatrelvir/ritonavir) / Pfizer |
ChiCTR2200059739: A single center, prospective, randomized controlled study of paxlovid compared to Lianhua Qingwen in shortening the negative time of novel coronavirus positive patients |
|
|
| Not yet recruiting | 4 | 220 | | Two namatvir tablets (pink, 150 mg each) combined with one ritonavir tablet (white, 100 mg each) were taken orally every 12 hours for 5 consecutive days. ;Lianhua Qingwen granule 6g/bag, take it with warm water after meals. Three times a day, one bag each time. Lianhua Qingwen Capsule 0.35g, orally, after meals, four capsules each time, three times a day. | Renji Hospital, Shanghai Jiaotong University School of Medicine ; Renji Hospital, Shanghai Jiaotong University School of Medicine, No | Coronavirus disease | | | | |
PEP, NCT05690646: Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery |
|
|
| Active, not recruiting | 4 | 491 | RoW | Nirmatrelvir/ritonavir, Ursodeoxycholic acid | China National Center for Cardiovascular Diseases | Cardiac Surgery | 03/23 | 01/26 | | |
ChiCTR2200060010: Open-label, head-to-head, randomized, controlled clinical study of Molnupiravir capsules and Paxlovid tablets in patients with mild and general type of COVID-19 in high-risk populations |
|
|
| Not yet recruiting | 4 | 100 | | Molnupiravir ;Paxlovid | Beijing Ditan Hospital Capital Medical University; Beijing Ditan Hospital Capital Medical University, Research project of Beijing Ditan Hospital, Capital Medical University | Novel coronavirus pneumonia (COVID-19) at high risk of severe disease | | | | |
NCT05697055: A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection |
|
|
| Recruiting | 4 | 410 | RoW | Azvudine, Nirmatrelvir-Ritonavir | Shandong Provincial Hospital, Central hospital Affiliated to Shandong First Medical University, The Second Affiliated Hospital of Shandong First Medical University, The Affiliated Hospital Of Southwest Medical University, Gansu Provincial Hospital, Rizhao People's Hospital | COVID-19 | 05/23 | 07/23 | | |
ChiCTR2300071309: A Retrospective Study Evaluating the Efficacy and Safety of Azovudine Compared to Paxlovid for the Non-early Treatment of Coronavirus Disease 2019 (COVID-19) in Participants with COVID-19 |
|
|
| Not yet recruiting | 4 | 160 | | No; No | Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Provincial Hospital Affiliated to Shandong First Medical University, Self-raised funds | Novel Coronavirus Pneumonia (COVID-19) | | | | |
ChiCTR2300068643: A randomized, single center, open label study for azvudine vs Paxlovid treatment for severe COVID-19 patients |
|
|
| Recruiting | 4 | 92 | | Azvudine 5mg / time, once a day; 300mg Nirmatrelvir + 100mg Ritonavir, twice a day | Xiang'an Hospital of Xiamen University; Xiang'an Hospital of Xiamen University, Research start-up funds of Xiamen University | Novel coronavirus infection (COVID-19) | | | | |
ChiCTR2300071537: Observation and Follow-up Study on Clinical Efficacy of Paxlovid in the Treatment of Adult Omicron Variant Infection |
|
|
| Recruiting | 4 | 350 | | Orally take Nirmatrelvir tables(300mg) and Ritonavir tables(100mg), 12h/time, for 5 consecutive days ;standard treatments | Shijiazhuang People's Hospital; Shijiazhuang People's Hospital, National Key Research and Development Program for Public Safety Risk Prevention and Emergency Technical Equipment Special Project; Traditional Chinese Medicine Emergency Special Project for COVID-19 | COVID-19 | | | | |
ChiCTR2300067872: A randomized, controlled and open clinical study evaluating the efficacy and safety of Sanhanhuashi granules versus Paxlovid in the treatment of mild/medium-sized Covid-19 |
|
|
| Not yet recruiting | 4 | 400 | | Sanhanhuashi granules ;Paxlovid | China-Japan Friendship Hospital; China-Japan Friendship Hospital, Jiangsu Kanion Pharmaceutical Co,. Ltd. | Covid-19 | | | | |
NCT06441955: Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program. |
|
|
| Active, not recruiting | 4 | 100 | US | Ritonavir-Boosted Nirmatrelvir (Paxlovid), Phramacotherapies, Physiological Evaluation, Immunologic Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Whole Genome Sequence, Multidisciplinary approach | Well- Konnect Healthcare Services and Research Firm, All of Us Research Program at the National Institute of Health | COVID-19, Long Haul | 09/30 | 09/30 | | |
ChiCTR2200060700: The therapeutic effect of paxlovid combined with conventional therapy in patients aged 60 and over with COVID-19 |
|
|
| Recruiting | 4 | 150 | | Paxlovid combined with routine treatment ;Routine treatment | The Ninth People Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Ninth People's Hospital, Funds for talent construction and scientific research start-up of the Ninth People Hospital Affiliated to Shanghai Jiao Tong University School of Medicine | COVID 19 | | | | |
| Recruiting | 4 | 30 | RoW | Nirmatrelvir/ritonavir, Paxlovid | Chinese PLA General Hospital | COVID-19, Renal Insufficiency, Chronic | 05/25 | 05/25 | | |
ChiCTR2200063778: Efficacy evaluation of nirmatrelvir/ritonavir tablets on SARSC-CoV-2 infection-induced myocardial injury |
|
|
| Not yet recruiting | 4 | 600 | | ; | Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, self-funded | Covid-19 | | | | |
| Completed | 3 | 822 | | JT001(VV116) ;Paxlovid | Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine; Vigonvita Life Sciences Co., Ltd., Vigonvita Life Sciences Co., Ltd. | Novel Coronavirus Pneumonia (COVID-19) | | | | |
NCT05682586: UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients |
|
|
| Recruiting | 3 | 60 | RoW | umbilical cord mesenchymal stem cells, paxlovid | Shanghai East Hospital | Mesenchymal Stem Cell, COVID-19 Pneumonia | 03/23 | 07/23 | | |
| Not yet recruiting | 3 | 2000 | Europe | Paxlovid, J0SAE30, Capsule, hard + tablet, Paxlovid | Helse Bergen HF, Helse- og omsorgsdepartementet (KlinBeForsk) | COVID-19SARS-CoV-2, COVID, Diseases [C] - Virus Diseases [C02] | | | | |
| Completed | 3 | 536 | Europe | Sotrovimab, Tixagevimab Cilgavimab, Nirmatrelvir Ritonavir | Azienda Ospedaliera Universitaria Integrata Verona, Agenzia Italiana del Farmaco, Azienda Sanitaria-Universitaria Integrata di Udine | COVID-19 | 10/23 | 10/23 | | |
| Recruiting | 3 | 70000 | Europe, RoW | Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine, Azithromycin, Convalescent plasma, Tocilizumab, Immunoglobulin, Synthetic neutralising antibodies, REGEN-COV, casirivimab and imdevimab, Aspirin, Colchicine, Baricitinib, Anakinra, Dimethyl fumarate, High Dose Corticosteroid, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid, nirmatrelvir/ritonavir, Baloxavir Marboxil, Xofluza, Oseltamivir, Tamiflu, Low-dose corticosteroids: Dexamethasone | University of Oxford, UK Research and Innovation, National Institute for Health Research, United Kingdom, Wellcome, Bill and Melinda Gates Foundation, Department for International Development, United Kingdom, Health Data Research UK, Medical Research Council Population Health Research Unit, NIHR Clinical Trials Unit Support Funding, NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Flu Lab | Severe Acute Respiratory Syndrome | 06/26 | 06/36 | | |
|
ChiCTR2200066811: A Multi-Center Single-Blind, Randomized, Controlled Trial Evaluating the SARS-CoV-2 Rebound rate after full-course treatment of JT001 (VV116) Compared to Paxlovid for the Early Treatment of Mild to Moderate Coronavirus Disease 2019 (COVID-19) |
|
|
| Completed | 3 | 478 | | JT001(VV116); Paxlovid | Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine | Corona Virus Disease 2019 (COVID-19) | | | | |
| Recruiting | 3 | 12000 | Canada | Paxlovid, Other | Unity Health Toronto, Canadian Institutes of Health Research (CIHR), Health Canada | COVID-19 | 01/24 | 01/25 | | |
| Recruiting | 3 | 2000 | Europe | Nirmatrelvir/ritonavir, Paxlovid tablets, Placebo, Placebo tablets | Haukeland University Hospital, University of Bergen, Oslo University Hospital, University of Oslo, St. Olavs Hospital, Norwegian University of Science and Technology | Post COVID-19 Condition, Unspecified, SARS-CoV2 Infection, COVID-19 | 04/24 | 04/26 | | |
| Active, not recruiting | 3 | 2200 | RoW | (Arm Closed) Nafamostat Mesilate, Nafabelltan, (Arm Closed) Enoxaparin, (Arm Closed) Dalteparin, (Arm Closed) Tinzaparin, (Arm Never Opened) Hyperimmune globulin, Nirmatrelvir-Ritonavir, Paxlovid, Remdesivir, Veklury | University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Australasian Society for Infectious Diseases, Hunter Medical Research Institute, Aotearoa Clinical Trials, Australian and New Zealand Intensive Care Research Centre | SARS-CoV-2 Infection (COVID-19) | 07/25 | 12/25 | | |
| Recruiting | 3 | 20000 | Europe, Canada, Japan, US, RoW | Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir | UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore | Community-acquired Pneumonia, Influenza, COVID-19 | 02/26 | 02/28 | | |
NCT05261139 / 2022-000075-39: EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease |
|
|
| Suspended | 2/3 | 160 | Europe, Japan, US, RoW | nirmatrelvir, ritonavir | Pfizer | COVID-19 | 07/26 | 07/26 | | |
|
2022-002447-22: A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19 |
|
|
| Not yet recruiting | 2 | 279 | Europe | Ritonavir, Nirmatrelvir, PF-07321332, Capsule, Film-coated tablet, RITONAVIR | Pfizer Inc., Pfizer Inc. | SARS-CoV-2 Infection, COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
| Not yet recruiting | 2 | 400 | Europe | PAXLOVID, Ritonavir, Film-coated tablet, Tablet | Karolinska Institutet, Pfizer Inc. | Patients with Post-Acute COVID syndrome (PACS) in which extensive clinical and biochemical examinations have been performed. PACS patients experience a wide variety of symptoms related to physical and cognitive function, including fatigue, dyspnea, “brain fog” or other cognitive symptoms, pain, depression, and gastrointestinal issues which significantly impact quality of life., Patients with Post-Acute COVID syndrome (PACS) which experience symptoms related to physical and cognitive function., Diseases [C] - Virus Diseases [C02] | | | | |
NCT05438602 / 2022-001362-35: A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System |
|
|
| Completed | 2 | 158 | Europe, Canada, US, RoW | Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir, Placebo for ritonavir | Pfizer | COVID-19 | 07/23 | 11/23 | | |
| Completed | 2 | 168 | US | Nirmatrelvir, Placebo, Ritonavir | Stanford University, Pfizer | Post-acute Sequelae of SARS-CoV-2 Infection, Long COVID | 08/23 | 09/23 | | |
EPIC-HOS, NCT05545319: A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19 |
|
|
| Withdrawn | 2 | 279 | Europe, US | Nirmatrelvir, Paxlovid, Ritonavir, Norvir, Placebo for nirmatrelvir | Pfizer | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization, Child, Hospitalized | 09/23 | 01/24 | | |
NCT05567952 / 2022-002827-36: A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir |
|
|
| Completed | 2 | 436 | Europe, Canada, US, RoW | nirmatrelvir, ritonavir, placebo for nirmatrelvir | Pfizer, Pfizer Inc. | COVID-19 | 09/23 | 02/24 | | |
PAXLC, NCT05668091: A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID. |
|
|
| Completed | 2 | 100 | US | Nirmatrelvir, Ritonavir, Placebo, sugar pill | Harlan M Krumholz, Pfizer | Long COVID | 04/24 | 08/24 | | |
| Active, not recruiting | 2 | 180 | Europe | Nirmatrelvir/ritonavir, Paxlovid, Placebo/ritonavir, Placebo | Karolinska Institutet, Karolinska University Hospital, Pfizer | Post-COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19, POTS - Postural Orthostatic Tachycardia Syndrome, Post COVID-19 Condition, Post-COVID Syndrome, Post COVID-19 Condition, Unspecified, Postinfectious Inflammation, Postinfectious Disorder | 11/24 | 11/24 | | |
| Active, not recruiting | 2 | 964 | US | Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control | Kanecia Obie Zimmerman | Long COVID, Long Covid19 | 12/24 | 03/25 | | |
| Active, not recruiting | 2 | 964 | US | Paxlovid 25 day dosing, Paxlovid 15 day dosing, Control | Kanecia Obie Zimmerman | Long COVID-19, Long COVID | 12/24 | 03/25 | | |
OPTICOV, NCT05587894: OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial |
|
|
| Recruiting | 2 | 256 | Europe | Paxlovid 5 days, Nirmatrevlir/ritonavir, Paxlovid 10 days, Veklury, remdesivir | ANRS, Emerging Infectious Diseases, University Hospital, Geneva | COVID-19, Immunodeficiency | 03/25 | 05/25 | | |
PLATCOV, NCT05041907: Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 |
|
|
| Recruiting | 2 | 3000 | RoW | Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™), Hydroxychloroquine, No treatment, Monoclonal antibodies, Fluoxetine, Molnupiravir, Sotrovimab, Ensitrelvir, Favipiravir, Ivermectin, Remdesivir | University of Oxford | COVID-19 | 01/27 | 01/27 | | |
NCT04746183: AGILE (Early Phase Platform Trial for COVID-19) |
|
|
| Active, not recruiting | 1/2 | 600 | Europe, RoW | CST-2: EIDD-2801, MK-4482, Molnupiravir, CST-2: Placebo, Placebo, Nitazoxanide, VIR-7832, VIR-7831, Sotrovimab, CST-5: Placebo, Favipiravir, Lagevrio, Paxlovid, nirmatrelvir and ritonavir | University of Liverpool, University of Southampton, Liverpool School of Tropical Medicine, Liverpool University Hospitals NHS Foundation Trust, University of Cambridge | Covid19 | 07/25 | 07/25 | | |
|
NCT05386433: Paxlovid in the Treatment of COVID-19 Patients With Uremia |
|
|
| Not yet recruiting | 1 | 40 | NA | Paxlovid, standard-of-care | Ruijin Hospital | COVID-19, Uremia | 07/22 | 08/22 | | |
ChiCTR2200058477: Clinical efficacy and safety of Paxlovid in the treatment of severe adult patients with SARS-Cov-2 infection: a multicenter, randomized, controlled study |
|
|
| Completed | 1 | 264 | | Standard COVID-19 Treatment Protocol ;Combined with Paxlovid | Ruijin Hospital, Shanghai Jiaotong University School of Medicine; Ruijin Hospital, Shanghai Jiaotong University School of Medicine, self-funded | Corona Virus Disease 2019, COVID-19 | | | | |
NCT05487040: A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease |
|
|
| Terminated | 1 | 15 | US | PF-07321332 (nirmatrelvir)/ritonavir, Paxlovid | Pfizer | COVID-19 | 07/23 | 07/23 | | |
NCT05898672: A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin |
|
|
| Completed | 1 | 12 | Europe | Rosuvastatin, Nirmatrelvir/ritonavir | Pfizer | Pharmacokinetics, Healthy Volunteers | 08/23 | 08/23 | | |
NCT05441215: A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women |
|
|
| Completed | 1 | 8 | Europe | nirmatrelvir, PF-07321332/ritonavir, ritonavir | Pfizer | Healthy Participants | 12/23 | 12/23 | | |
NCT05386472: A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19 |
|
|
| Recruiting | 1 | 49 | US | nirmatrelvir, PF-07321332, ritonavir | Pfizer | COVID-19 | 02/25 | 07/25 | | |
NCT06397144: A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants |
|
|
| Not yet recruiting | 1 | 28 | NA | Paxlovid, Nirmatrelvir/ritonavir commercial tablets, Nirmatrelvir/ritonavir, Nirmatrelvir/ritonavir FDC test tablets formulation 1, Nirmatrelvir/ritonavir FDC test tablets formulation 2 | Pfizer | Biological Availability, Healthy Participants | 06/25 | 06/25 | | |
ChiCTR2200059726: Clinical study of YinQiaoSan combined with SiNiSan in the treatment of sub-designated hospital Omicron COVID-19 infection |
|
|
| Recruiting | N/A | 132 | | YinQiaoSan, One dose daily, divided into two doses in the morning and evening ;YinQiaoSan and SiNiSan, One dose daily, divided into two doses in the morning and evening ;Needle burial at acupuncture points (Dazhui, Hegu, Quchi, Waiguan), daily only ;Orally PF-07321332 100 mg + Paxlovid 300 mg, q12h | Shuguang Hospital Affiliated of Shanghai University of Traditional Chinese Medicine ; Shuguang Hospital Affiliated of Shanghai University of Traditional Chinese Medicine, self-funded | Omicron COVID-19 | | | | |
ChiCTR2200060589: Clinical application of "ZengnengJiedu Prescription" in the treatment of novel coronavirus pneumonia |
|
|
| Not yet recruiting | N/A | 80 | | Zengneng Jiedu Recipe+paxlovid ;Placebo+paxlovid | Shanghai Tenth People's Hospital; Shanghai Tenth People's Hospital, Self-financing | COVID-19 | | | | |
ChiCTR2200059502: Randomized controlled clinical study of Yiqing oral liquid and paxlovid in the treatment of novel coronavirus infection |
|
|
| Not yet recruiting | N/A | 80 | | Paxlovid+Yiqing Oral Liquid ;Paxlovid+ Yiqing Oral Liquid Placebo | Huashan Hospital Affiliated to Fudan University; Huashan Hospital Affiliated to Fudan University, State Administration of Traditional Chinese Medicine | Novel Coronavirus Pneumonia (COVID-19) | | | | |
ChiCTR2200059743: Study on the changed characteristics of glycolipid and immune metabolism in patients with coronavirus disease 2019 (COVID-19) treated by Paxlovid |
|
|
| Recruiting | N/A | 310 | | Paxlovid ;No | Renji Hospital, Shanghai Jiaotong University School of Medicine ; Renji Hospital, Shanghai Jiaotong University School of Medicine, No | Covid-19 | | | | |
NCT05813600: Efficacy and Safety of Nirmatrelvir/Ritonavir for Treating Omicron Variant of COVID-19 |
|
|
| Completed | N/A | 58 | RoW | Nirmatrelvir/Ritonavir | Xiangao Jiang | Omicron Variant of COVID-19 | 12/22 | 12/22 | | |
ChiCTR2200059392: A real world study comparing the efficacy and safety of Jingyin Qinghua granule and paxlovid in the treatment of novel coronavirus pneumonia (covid-19) with high risk factors |
|
|
| Not yet recruiting | N/A | 200 | | Basic treatment + Jingyin Qinghua formula, 2 bags / time, tid × 7 days ;Basic treatment + paxlovid (nematevir 300mg + ritonavir 100mg), Q12h × Five days. | Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine; Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine, Shanghai Municipal Health Commission | COVID-19 | | | | |
ChiCTR2200059501: A single-arm clinical study to evaluate the safety of the investigational drug as Nirmatrelvir Tablets/Ritonavir Tablets in the treatment of maintenance dialysis patients with Covid-19 infection and to evaluate the efficacy of the investigational drug with non-investigational drug treatment as the control group |
|
|
| Recruiting | N/A | 200 | | Nirmatrelvir Tablets/Ritonavir Tablets ;None | Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, self-funded | Novel Coronavirus Pneumonia (COVID-19) | | | | |
ChiCTR2200059391: A real world study comparing the efficacy and safety of Jingyin granule and Paxlovid in the treatment of novel coronavirus pneumonia (covid-19) with high risk factors |
|
|
| Not yet recruiting | N/A | 200 | | Basic treatment + Jingyin granules, 2 bags / time, tid × 7 days; ;Basic treatment + paxlovid (nematevir 300mg + ritonavir 100mg), Q12h, 5 days | Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine; Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine, Shanghai Municipal Health Commission | COVID-19 | | | | |
ChiCTR2200059390: A randomized controlled study on the efficacy and safety of Huashi Baidu granule in the treatment of novel coronavirus pneumonia (COVID-19) with high risk factors |
|
|
| Recruiting | N/A | 300 | | Basic treatment + Huashi Baidu granule, 1 pack / time, 3 times a day, for 7 days ;Basic treatment + paxlovid (nematevir 300mg + ritonavir 100mg), q12h, 5 days ;Basic treatment + Huashi Baidu granule for 7 days + paxlovid for 5 days | Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine; Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine, Shanghai Municipal Health Commission | Novel Coronavirus Pneumonia (COVID-19) | | | | |
ChiCTR2300069704: Efficacy and safety of Nirmatrelvir/Ritonavir for treating Omicron variant of COVID-19 |
|
|
| Completed | N/A | 58 | | No ;No | Wenzhou Central Hospital ; Wenzhou Central Hospital, self-financing | COVID-19 | | | | |
ChiCTR2200067137: A randomized, controlled clinical study to evaluate the efficacy and safety of GST-HG171 tablets in combination with ritonavir in adult subjects with mild/moderate COVID-19 |
|
|
| Recruiting | N/A | 60 | | GST-HG171 tablets combined with ritonavir ;Placebo ;Paxlovid | The First Affiliated Hospital of Guangzhou Medical University; The Third People's Hospital of Shenzhen; The First Affiliated Hospital of Guangzhou Medical University, Fujian Akeylink Biotechnology Co., Ltd. | SARS-CoV-2 infection | | | | |
NCT05642910: The Efficacy of Azvudine and Paxlovid in High-risk Patients With COVID-19: A Prospective Randomized Controlled Trial |
|
|
| Recruiting | N/A | 540 | RoW | Azvudine, treatment group, Paxlovid group, control group | Southeast University, China, Hohhot First Hospital, Hohhot, Inner Mongolia, China | SARS-CoV-2 Infection | 01/23 | 04/23 | | |
NCT05749445: Appropriate Evaluation of Antiviral Therapy With Nirmatrelvir-ritonavir in Hospitalized Patients |
|
|
| Recruiting | N/A | 200 | RoW | Nirmatrelvir-Ritonavir, PAXLOVID | First People's Hospital of Hangzhou, Hangzhou Cancer Hospital, First People's Hospital of Lin'an District, First People's Hospital of Yuhang District | Hospitalized Patients | 04/23 | 04/23 | | |
ChiCTR2200065948: Investigation and analysis of influencing factors of COVID-19 infection and prognosis based on patients vaccination status, and clinical outcomes and safety evaluation of patients treated with Paxlovid—a prospective nested case-control study in the real world setting |
|
|
| Recruiting | N/A | 200000 | | Nil ;Nil | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Science and Technology Commission of Shanghai Municipality (20DZ2261200) | respiratory virus infectious disease | | | | |
ChiCTR2300067709: Comparing the effects of paxlovid with azvudine in patients with COVID-19 after lung transplantation: a single-center, real-world study, bidirectional cohort study |
|
|
| Not yet recruiting | N/A | 30 | | N/A ;N/A | West China Hospital, Sichuan University; West China Hospital, Sichuan University, Other | COVID-19 | | | | |
NCT05532852: Efficacy and Safety Evaluation of Paxlovid for COVID-19: a Real-world Case-control Study |
|
|
| Recruiting | N/A | 728 | RoW | standard-of-care plus Paxlovid, standard-of-care | Ruijin Hospital | COVID-19 Pneumonia | 06/23 | 10/23 | | |
NCT05792865: A Registry Study of Patients Hospitalized With Confirmed COVID-19 |
|
|
| Not yet recruiting | N/A | 488 | NA | paxlovid, paxlovid within initial 5 days, No paxlovid, Paxlovid, Paxlovid outside of the initial 5 days | Beijing Chao Yang Hospital | COVID-19 | 06/23 | 12/23 | | |
NCT05263908: A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19 |
|
|
| Completed | N/A | 3346 | Japan | nirmatrelvir / ritonavir, PAXLOVID PACK | Pfizer | SARS-CoV-2 Infection | 07/23 | 07/23 | | |
| Recruiting | N/A | 660 | RoW | Oral Antiviral, Paxlovid, Lagevrio | Clinical Research Centre, Malaysia | COVID-19 | 07/23 | 07/23 | | |
ChiCTR2300078007: A multicenter randomized controlled study to evaluate the efficacy and safety of a recombinant human monoclonal antibody against SARS-CoV-2 for injection (F61 injection) in COVID-19 patients with kidney injury |
|
|
| Completed | N/A | 200 | | F61 injection+standard treatment; Standard treatment; F61 injection+standard treatment; Standard treatment (Azvudine, oxygen therapy and anticoagulant therapy, etc/Paxlovid, oxygen therapy and anticoagulant therapy, etc) | The First Medical Center of Chinese PLA General Hospital; Chinese PLA General Hospital, Independent Investigator-Initiated Trial | COVID-19 patients with kidney injury | | | | |
| Active, not recruiting | N/A | 211 | Europe | Nirmatrelvir/ritonavir, Paxlovid, Molnupiravir, Lagevrio | Universidade do Porto, Faculty of Medicine (FMUP), Centro de Investigação em Tecnologias e Serviços de Saúde (CINTESIS), Rede de Investigação em Saúde (RISE), Laboratório Associado | COVID-19 | 01/24 | 06/24 | | |
NCT06349655: The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19 |
|
|
| Completed | N/A | 32864 | RoW | Azvudine, Paxlovid, Nirmatrelvir/Ritonavir | The First Affiliated Hospital of Zhengzhou University, Henan Provincial Chest Hospital, The Affiliated Infectious Disease Hospital of Zhengzhou University, The Fifth People's Hospital of Anyang, Shangqiu Municipal Hospital, Nanyang Central Hospital, Luoyang Central Hospital, Guangshan County People's Hospital, Fengqiu County People's Hospital | COVID-19, Azvudine | 01/24 | 03/24 | | |
| Completed | N/A | 2478 | US | Pharmacist Care, AFM Pool Care | Kaiser Permanente | COVID-19, Quality of Care | 12/23 | 01/24 | | |
NCT06085924: A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19. |
|
|
| Recruiting | N/A | 1 | RoW | SoC, Disease description | Pfizer | COVID-19 | 08/24 | 08/24 | | |
ChiCTR2200066990: Clinical Efficacy and Safety Analysis of paxlovid in the Treatment of Elderly sars-cov-2 Omicron infection. |
|
|
| Recruiting | N/A | 140 | | No ;No | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, self financing | sars-cov-2 Omicron infection | | | | |
NCT05624840: Safety and Clinical and Virologic Outcomes in CKD Patients Treated With Nirmatrelvir-ritonavir |
|
|
| Completed | N/A | 85 | RoW | Nirmatrelvir/ritonavir, Paxlovid | Chinese University of Hong Kong | COVID-19, Chronic Kidney Disease stage4, Chronc Kidney Disease Stage 5 | 01/23 | 02/23 | | |
NCT06291831: A Study to Learn About the Use of Paxlovid in Patients With COVID-19 in the Kingdom of Bahrain. |
|
|
| Completed | N/A | 3000 | RoW | nirmatrelvir, ritonavir, Controls | Pfizer | COVID-19 | 05/24 | 05/24 | | |
NCT06016556: A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia |
|
|
| Completed | N/A | 250 | RoW | nirmatrelvir, ritonavir, Paxlovid | Pfizer | Covid-19 | 04/24 | 04/24 | | |
NCT05997485: A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco |
|
|
| Withdrawn | N/A | 150 | NA | Nirmatrelvir/Ritonavir, Paxlovid | Pfizer | COVID-19 Drug Treatment | 06/24 | 06/24 | | |
ChiCTR2300071753: Plasma concentration determination and pharmacokinetics study of Nirmatrelvir/Ritonavir tablets in children |
|
|
| Not yet recruiting | N/A | 50 | | None | Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University; Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University | COVID-19 | | | | |
NCT05996770: Evaluation of the Safety and Efficacy of Azvudine and Paxlovid in the Treatment of Hospitalized Patients With COVID-19 |
|
|
| Not yet recruiting | N/A | 1500 | NA | | Xiao Li，MD | Paxlovid, Azvudine, COVID-19 | 07/24 | 12/24 | | |
COVID, NCT06610643: Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients |
|
|
| Not yet recruiting | N/A | 40 | RoW | combination therapy, remdesivir and Nirmatrelvir/Ritonavir, SOC | National Taiwan University Hospital | COVID-19, SARS-CoV-2, Immunocompromised | 09/26 | 12/26 | | |
